Literature DB >> 28557251

Evidence for the association of Epstein-Barr Virus in breast cancer in Indian patients using in-situ hybridization technique.

Trupti Pai1,2, Sudeep Gupta3, Mamta Gurav1,2, Shona Nag4, Tanuja Shet2, Asawari Patil2, Sangeeta Desai1,2.   

Abstract

Epstein-Barr Virus (EBV) is etiologically linked to Burkitt lymphoma (BL), nasopharyngeal carcinoma, post-transplant lymphomas, Hodgkin disease, and possibly other tumors. However, the association of oncogenic EBV with breast carcinoma (BC) is still controversial and a matter of debate. We aimed to study the presence of EBV genome in BC cases in Indian patients and its association with the clinicopathological features. The formalin fixed paraffin embedded tissues from 83 women with primary invasive BC were studied for the presence of EBV by in-situ hybridization (ISH) technique for Epstein-Barr Virus Encoded RNA (EBER) with appropriate controls. Correlation of EBER-ISH positivity with clinicopathological features was performed using Fisher exact test and P<.05 was considered as significant. Eighty-three BC cases were comprised of 47 (56.5%) triple negative breast cancers (TNBC), 17 (20.5%) hormone positive and 19 (22.9%) HER2 positive cases. Of 83 cases, 25 cases (30.1%) were positive for EBER-ISH test. The positivity was restricted to the tumor cells and not seen in the surrounding breast lobules. EBER-ISH positivity was statistically associated with larger tumor size (52.6% in >5 cm tumors vs 19.3% in ≤5 cm; P=.014) and with TNBCs (21/47 [44.7%] in TNBCs vs 4/36 [11.1%] in non-TNBCs; P=.001). A possible causal association of EBV in BC cases in Indian patients is suggested by high frequency of EBER-ISH positivity noted in our study. This might have therapeutic significance because of the possible role of EBV specific cytotoxic T cells in targeting EBV associated tumor cells and can be considered as a potential targeted therapy. To the best of our knowledge, this is the first study from India to address this issue using EBER-ISH technique.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  EBER-ISH; Epstein-Barr Virus; TNBC; breast cancer

Mesh:

Year:  2017        PMID: 28557251     DOI: 10.1111/tbj.12828

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  7 in total

1.  Epstein-Barr Virus Infection and Increased Sporadic Breast Carcinoma Risk: A Meta-Analysis.

Authors:  Qing'e Jin; Jianrong Su; Donghui Yan; Shanna Wu
Journal:  Med Princ Pract       Date:  2019-07-17       Impact factor: 1.927

Review 2.  Oncogenic Viruses and Breast Cancer: Mouse Mammary Tumor Virus (MMTV), Bovine Leukemia Virus (BLV), Human Papilloma Virus (HPV), and Epstein-Barr Virus (EBV).

Authors:  James S Lawson; Brian Salmons; Wendy K Glenn
Journal:  Front Oncol       Date:  2018-01-22       Impact factor: 6.244

3.  Paraffin-embedding for large volume bio-tissue.

Authors:  Ouyang Zhanmu; Xiaoying Yang; Hui Gong; Xiangning Li
Journal:  Sci Rep       Date:  2020-07-28       Impact factor: 4.379

4.  Detection of Epstein-Barr Virus in 130 Cases of Eyelid Sebaceous Gland Carcinoma Using In Situ Hybridization.

Authors:  Huanhuan Gao; Lijuan Tang; Jianxian Lin; Wenxin Zhang; Yongping Li; Ping Zhang
Journal:  J Ophthalmol       Date:  2020-03-30       Impact factor: 1.909

5.  Human Mammary Tumor Virus, Human Papilloma Virus, and Epstein-Barr Virus Infection Are Associated With Sporadic Breast Cancer Metastasis.

Authors:  Mohammad Al Hamad; Ismail Matalka; Mazhar Salim Al Zoubi; Ivana Armogida; Rawan Khasawneh; Maysa Al-Husaini; Maher Sughayer; Saied Jaradat; Amjad D Al-Nasser; Chiara Maria Mazzanti
Journal:  Breast Cancer (Auckl)       Date:  2020-11-24

Review 6.  Epstein-Barr Virus Association with Breast Cancer: Evidence and Perspectives.

Authors:  Claudia Arias-Calvachi; Rancés Blanco; Gloria M Calaf; Francisco Aguayo
Journal:  Biology (Basel)       Date:  2022-05-24

Review 7.  Pathobiologic Roles of Epstein-Barr Virus-Encoded MicroRNAs in Human Lymphomas.

Authors:  Mohsen Navari; Maryam Etebari; Mostafa Ibrahimi; Lorenzo Leoncini; Pier Paolo Piccaluga
Journal:  Int J Mol Sci       Date:  2018-04-12       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.